PE20030275A1 - g-LACTONAS SUSTITUIDAS COMO ANTAGONISTAS DE NMDA - Google Patents
g-LACTONAS SUSTITUIDAS COMO ANTAGONISTAS DE NMDAInfo
- Publication number
- PE20030275A1 PE20030275A1 PE2002000601A PE2002000601A PE20030275A1 PE 20030275 A1 PE20030275 A1 PE 20030275A1 PE 2002000601 A PE2002000601 A PE 2002000601A PE 2002000601 A PE2002000601 A PE 2002000601A PE 20030275 A1 PE20030275 A1 PE 20030275A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- methyl
- aliphatic radical
- phenylamine
- ona
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000003254 radicals Chemical class 0.000 abstract 6
- -1 2,4,6-TRICHLOROPHENYL Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 2
- 206010008118 cerebral infarction Diseases 0.000 abstract 2
- XRAKCYJTJGTSMM-UHFFFAOYSA-N 2-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1Cl XRAKCYJTJGTSMM-UHFFFAOYSA-N 0.000 abstract 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 abstract 1
- WOYZXEVUWXQVNV-UHFFFAOYSA-N 4-phenoxyaniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC=C1 WOYZXEVUWXQVNV-UHFFFAOYSA-N 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical group OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A g-LACTONAS SUSTITUIDAS DE FORMULA I DONDE R1 ES ARILO, HETEROARILO, OPCIONALMENTE LIGADO A TRAVES DE UN RADICAL ALQUILENO C1-C6, RADICAL ALIFATICO C1-C10, ENTRE OTROS; R2 ES RADICAL ALIFATICO C1-C10; R3 ES ARILO; R4 ES H; R3 Y R4 JUNTOS FORMAN UN RADICAL C3-C7 CON LA CONDICION QUE R2 ES ARILO, RADICAL ALIFATICO C1-C10, RADICAL ALIFATICO C2-C10; EXCEPTO LOS COMPUESTOS CUANDO R1 ES 2,4,6-TRICLOROFENILO, TOSILO; R2 ES METILO; R3 ES FENILO; R4 ES H. SON COMPUESTOS PREFERIDOS 3-(2-CLORO-4-FLUORO-FENILAMINO)-5-(4-FLUORO-FENIL)-5-METIL-DIHIDRO-FURAN-2-ONA; 5-METIL-3-(4-FENOXI-FENILAMINO)-5-FENIL-DIHIDRO-FURAN-2-ONA; 3-(2-CLORO-FENILAMINO)-5-(4-FLUORO-FENIL)-5-METIL-DIHIDRO-FURAN-2-ONA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS PUEDEN SER UTILES PARA EL TRATAMIENTO DEL DOLOR, DOLOR CRONICO, NEUROPATICO, PROFILAXIS DE ENFERMEDADES NEURODEGENERATIVAS COMO ALZHEIMER, PARKINSON, HUNTINGTON, APOPLEJIA, ISQUEMIA CEREBRAL, INFARTO CEREBRAL, EDEMA CEREBRAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10132725A DE10132725A1 (de) | 2001-07-05 | 2001-07-05 | Substituierte γ-Lactonverbindungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030275A1 true PE20030275A1 (es) | 2003-04-26 |
Family
ID=7690792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000601A PE20030275A1 (es) | 2001-07-05 | 2002-07-04 | g-LACTONAS SUSTITUIDAS COMO ANTAGONISTAS DE NMDA |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6956055B2 (es) |
| EP (1) | EP1406888B1 (es) |
| AR (1) | AR036130A1 (es) |
| AT (1) | ATE327226T1 (es) |
| CY (1) | CY1105275T1 (es) |
| DE (2) | DE10132725A1 (es) |
| DK (1) | DK1406888T3 (es) |
| ES (1) | ES2266524T3 (es) |
| PE (1) | PE20030275A1 (es) |
| PT (1) | PT1406888E (es) |
| WO (1) | WO2003004483A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| US8214813B2 (en) * | 2007-01-12 | 2012-07-03 | Microsoft Corporation | Code optimization across interfaces |
| US7985375B2 (en) | 2007-04-06 | 2011-07-26 | Qiagen Gaithersburg, Inc. | Sample preparation system and method for processing clinical specimens |
| US8703492B2 (en) | 2007-04-06 | 2014-04-22 | Qiagen Gaithersburg, Inc. | Open platform hybrid manual-automated sample processing system |
| KR20180053432A (ko) | 2008-08-12 | 2018-05-21 | 진판델 파마슈티컬스 인코포레이티드 | 질환 위험 인자의 식별 방법 |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| WO2011063139A1 (en) | 2009-11-18 | 2011-05-26 | Qiagen | Laboratory central control unit method and system |
| CN103501783A (zh) | 2011-01-10 | 2014-01-08 | 金帆德尔制药股份有限公司 | 用于治疗阿尔茨海默病的方法和药物产品 |
| CN113234036B (zh) * | 2021-05-12 | 2023-07-14 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0386839B1 (en) | 1989-03-08 | 1997-01-15 | Merck Sharp & Dohme Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| DE19536809A1 (de) | 1995-10-02 | 1997-04-03 | Basf Ag | Heterocyclisch substituierte Salicylsäurederivate |
| GB9617305D0 (en) | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
| GB9706294D0 (en) | 1997-03-26 | 1997-05-14 | Glaxo Wellcome Spa | Heterocyclic compound |
-
2001
- 2001-07-05 DE DE10132725A patent/DE10132725A1/de not_active Withdrawn
-
2002
- 2002-07-03 EP EP02743260A patent/EP1406888B1/de not_active Expired - Lifetime
- 2002-07-03 DE DE50206910T patent/DE50206910D1/de not_active Expired - Lifetime
- 2002-07-03 WO PCT/EP2002/007380 patent/WO2003004483A1/de active IP Right Grant
- 2002-07-03 AT AT02743260T patent/ATE327226T1/de not_active IP Right Cessation
- 2002-07-03 PT PT02743260T patent/PT1406888E/pt unknown
- 2002-07-03 ES ES02743260T patent/ES2266524T3/es not_active Expired - Lifetime
- 2002-07-03 DK DK02743260T patent/DK1406888T3/da active
- 2002-07-04 PE PE2002000601A patent/PE20030275A1/es not_active Application Discontinuation
- 2002-07-05 AR ARP020102526A patent/AR036130A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 US US10/751,741 patent/US6956055B2/en not_active Expired - Fee Related
-
2006
- 2006-08-21 CY CY20061101157T patent/CY1105275T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2266524T3 (es) | 2007-03-01 |
| AR036130A1 (es) | 2004-08-11 |
| WO2003004483A1 (de) | 2003-01-16 |
| PT1406888E (pt) | 2006-10-31 |
| EP1406888B1 (de) | 2006-05-24 |
| DE10132725A1 (de) | 2006-08-03 |
| DK1406888T3 (da) | 2006-09-18 |
| US20040171677A1 (en) | 2004-09-02 |
| DE50206910D1 (de) | 2006-06-29 |
| US6956055B2 (en) | 2005-10-18 |
| ATE327226T1 (de) | 2006-06-15 |
| CY1105275T1 (el) | 2010-03-03 |
| EP1406888A1 (de) | 2004-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030702A1 (es) | Inhibidores de pde9 para tratamiento de transtornos cardiovasculares | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| PE20090042A1 (es) | Analogos de ciclopamina | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| AR066882A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR016523A1 (es) | Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| PE20141702A1 (es) | Compuestos de carbamato y preparacion y uso de los mismos | |
| PE20220569A1 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos | |
| PE20080830A1 (es) | Compuestos derivados de sulfonilo que modulan el receptor cb2 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR066881A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
| PE20110397A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| PE20081530A1 (es) | Nuevos compuestos 617 | |
| NO20071476L (no) | Antidiuretiske midler. | |
| PE20161366A1 (es) | Heterociclil-sulfonas sustituidas con heteroarilo | |
| AR063906A1 (es) | Compuestos quimicos derivados del indazol, una composicion farmaceutica y procesos de prpeparacion de los compuestos | |
| AR021087A1 (es) | Pirimidin-4-iliden-alquilamina 2,3-sustituida 5,6-anillada, composicion para controlar y prevenir plagas, uso de dichos compuestos para proteger a lasplantas contra la infestacion por microorganismos fitopatogenicos, metodo para controlar o prevenir la infestacion de plantas cultivadas por microorga | |
| NO166129C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-9h-pyrido (3,4-b)indoler. | |
| PE20030275A1 (es) | g-LACTONAS SUSTITUIDAS COMO ANTAGONISTAS DE NMDA | |
| PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
| EA200970793A1 (ru) | Модуляторы рецепторов, активируемых пролифераторами пероксисом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |